MICROHEALTH MEANS BETTER PATIENT CONNECTIONS.

MicroHealth provides innovative patient connections to help inform hemophilia treatment decisions and stay on track.

INDICATIONS:
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of Use
ELOCTATE is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

Please see additional Important Safety Information and full Prescribing Information.

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] + microhealth

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]

KEEPING PATIENTS ON TRACK

MicroHealth* is the world's largest digital health network for the hemophilia community. By working with MicroHealth, you and your team help keep your patients on track and stay connected via mobile and web apps.

MicroHealth is proudly sponsored by Sanofi Genzyme.

*MicroHealth is an independent health network for digital hematology. Sanofi Genzyme does not have access to any personal information collected by MicroHealth.

ELOCTATE®
[Antihemophilic Factor (Recombinant), Fc Fusion Protein]

WHAT YOU NEED TO KNOW

- Treatment monitoring, view patient's bleeds
- Review adherence, receive clinical notifications when patients are non-compliant
- Identify patients who may benefit from additional support
- Stay connected with patients via mobile and web apps

Patients on ELOCTATE can access information about financial assistance and other patient support services available to help support them throughout their treatment.

SELECTED IMPORTANT SAFETY INFORMATION

WARNING AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic- type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Immediately discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur.

Please see additional Important Safety Information and full Prescribing Information.

ELOCTATE®
[Antihemophilic Factor (Recombinant), Fc Fusion Protein]

GETTING STARTED IS EASY

Set up an account for your practice quickly and easily by visiting MicroHealth.org.

- Choose what types of notifications to get about your patients, such as bleeds or when adherence drops below a certain level
- When your patients connect with you on MicroHealth, you can see their treatment schedules, bleed logs, adherence level ratio, their factor and dosage, even pictures they've shared of bleeds and what caused them
- Send and receive private messages, and accept appointments if necessary. Patients receive communications from you via the web or on their mobile devices.

SELECTED IMPORTANT SAFETY INFORMATION

Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE. Patients using ELOCTATE should be monitored for the development of Factor VIII inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor VIII levels have been achieved and maintained.

Sign up your center at MicroHealth.org.
Then inform your patients your center is using the app.

Please see additional Important Safety Information and full Prescribing Information.

The cloud-based, user-friendly app that gives medical professionals access to patient information by tracking treatment regimen in a smart and synched format*

**MicroHealth is an independent health network for digital hematology. Sanofi Genzyme does not have access to any personal information collected by MicroHealth*



Scan the QR code to sign-up and get started.

RESOURCES TO SUPPORT YOUR PATIENTS

Visit ELOCTATEPRO.COM

Learn about all the resources, and support, and financial assistance options available to your patients, including Free Trial Plus, our CoPay Program, and our Factor Access Program.

Not valid where prohibited by law. Sanofi Genzyme reserves the right to modify or discontinue the programs at any time. Program details provided upon registration. Free Trial Plus and Copay Program not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Copay program savings may vary depending on patients' out-of-pocket costs.

ELOCTATE®
[Antihemophilic Factor (Recombinant), Fc Fusion Protein]

INDICATIONS

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of Use
ELOCTATE is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Immediately discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur. Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE. Patients using ELOCTATE should be monitored for the development of Factor VIII inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor VIII levels have been achieved and maintained. Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII. If central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia, and catheter-site thrombosis should be considered.

ADVERSE REACTIONS: The most frequently occurring adverse reactions (incidence >0.5% of subjects) reported in previously treated patients (PTPs) clinical trials were arthralgia, malaise, myalgia, headache, and rash. The most frequently occurring adverse reactions (incidence ≥1.0% of subjects) reported in previously untreated patients (PUPs) clinical trials were Factor VIII inhibition, device-related thrombosis, and rash papular.

Please see full Prescribing Information.

SANOFI GENZYME

MAT-US-2108466-v1.0-11/2021